Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesFaeth Therapeutics, Inc.

Faeth Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.0501 USD -10.00 ( 45.35%)
Last update at 2026-11-09T18:16:00Z
VOLUME
2109513
Market Cap
913.98M

Momentum Score

…

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.45
Low
16.64
High
52 Week Price Range
7.45
Low
42.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Faeth Therapeutics, Inc. is a publicly listed, clinical-stage biopharmaceutical company; publicly available details about its pipeline and programs are limited. Long-term growth drivers could include positive clinical data, regulatory approvals and strategic partnerships that may support commercialization and broader market access.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
22.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.08
ROE
-195.26%
Net Debt
-7.16M
ROCE
-112.88%
Diluted EPS TTM
-55.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.09M -30.16M -34.10M -48.59M -36.79M
Net income -21.09M -30.16M -34.10M -48.59M -36.79M
Selling general administrative 11.33M 13.04M 18.66M 19.80M -
Selling and marketing expenses - - 0.10M - -
Gross profit - -0.55M -0.57M -1.81M -0.69M
Reconciled depreciation 0.14M 1.32M 1.35M 1.35M -
Ebit -21.05M -30.07M -37.06M -48.37M -36.12M
Ebitda -20.91M -29.52M -33.39M -46.56M -35.44M
Depreciation and amortization 0.14M 0.55M 3.68M 1.81M 0.69M
Operating income -22.29M -31.66M -37.06M -49.12M -37.48M
Other operating expenses 22.29M 31.66M 37.06M 49.12M 37.48M
Interest expense 0.03M 0.09M 0.14M 0.22M 0.67M
Interest income 1.24M 2.55M 3.62M 1.78M -
Net interest income 1.21M 2.46M 3.48M 1.56M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 22.29M 31.11M 36.49M 47.31M 36.80M
Cost of revenue - 0.55M 0.57M 1.81M 0.69M
Total other income expense net 1.20M 1.51M 2.96M 0.53M 0.69M
Net income from continuing ops -21.09M -30.16M -34.10M -48.59M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 22.90M 45.36M 74.37M 118.38M 153.22M
Other current assets 0.32M 0.59M 1.49M 1.47M 0.92M
Total liab 4.31M 6.97M 9.48M 14.97M 6.71M
Total stockholder equity 18.59M 38.39M 64.89M 103.41M 146.51M
Other current liab 2.11M 2.89M 1.51M 2.46M 1.75M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -283.14M -262.05M -231.90M -197.79M -149.21M
Other assets - - - -0.00M -
Cash 8.67M 9.99M 13.01M 17.80M 7.16M
Total current liabilities 4.25M 5.45M 5.64M 9.07M 4.89M
Net debt -7.16M -6.15M -6.80M -9.76M -4.80M
Short term debt 1.45M 2.32M 2.44M 2.13M 0.68M
Short long term debt total 1.51M 3.85M 6.21M 8.03M 2.35M
Other stockholder equity 301.73M 300.45M 297.00M 302.20M 296.05M
Total current assets 21.51M 41.93M 67.25M 108.59M 148.54M
Short term investments 12.52M 31.34M 52.75M 89.32M 140.46M
Accounts payable 0.69M 0.24M 1.69M 4.47M 2.46M
Accumulated other comprehensive income 0.00M -0.01M -0.21M -1.00M -0.33M
Non currrent assets other 0.02M 0.05M 0.09M 0.06M 0.04M
Non current assets total 1.40M 3.43M 7.12M 9.79M 4.68M
Capital lease obligations 1.51M 3.85M 6.21M 8.03M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 19.54M 22.59M 38.43M 50.26M -
Total cashflows from investing activities 19.77M 22.44M 38.41M 49.95M -143.12M
Net borrowings -0.65M -0.81M -0.76M -0.63M -
Total cash from financing activities -0.65M -0.79M -11.17M -0.29M 163.94M
Net income -21.09M -30.16M -34.10M -48.59M -36.79M
Change in cash -1.33M -3.02M -4.78M 10.64M -9.44M
Begin period cash flow 9.99M 13.01M 17.80M 7.16M 16.60M
End period cash flow 8.67M 9.99M 13.01M 17.80M 7.16M
Total cash from operating activities -20.45M -24.67M -32.02M -39.03M -30.26M
Issuance of capital stock - - - 0.00M -
Depreciation 0.14M 1.32M 1.35M 1.35M 0.69M
Sale purchase of stock -0.00M 0.00M -10.38M 0.00M -
Other cashflows from financing activities -0.00M -0.01M -0.03M - 23.60M
Capital expenditures 0.02M 0.15M 0.18M 0.32M 2.03M
Change in working capital -1.59M -0.49M -4.33M 1.01M 0.12M
Stock based compensation 1.27M 3.13M 4.45M 5.81M 5.66M
Other non cash items 0.81M 1.52M 0.60M 1.40M 0.06M
Free cash flow -20.47M -24.82M -32.20M -39.35M -32.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
FTH
Faeth Therapeutics, Inc.		 -10.00
45.35%		 12.05 - - - 5.84 1.36
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

1405 Research Boulevard, Rockville, MD, United States, 20850

240 243 8000

https://www.faeththerapeutics.com

29

Name Title Year Born
Mr. Josiah Craver CPA Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer NA
Mr. Christopher W. Gerry J.D. General Counsel & Secretary 1980
Mr. Anand Parikh Esq., J.D. CEO, President & Chair 1986
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. Scientific Co-Founder 1971
Dr. Lewis clayton Cantley Ph.D. Scientific Co-Founder 1949
Dr. Scott W. Lowe Ph.D. Scientific Co-Founder NA
Dr. Gregory J. Hannon Ph.D. Scientific Co-Founder NA
Dr. Karen H. Vousden Ph.D. Scientific Co-Founder 1958
Mr. Oliver Maddocks Ph.D. Co-Founder & Chief Scientific Officer NA
Dr. Benjamin Hopkins Ph.D. Scientific Co-Founder NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…